Antengene Corporation announced its appointment of Zhinuan Yu, Ph.D., as Corporate Vice President (CVP) of Biometrics and Regulatory Enabling Functions. Zhinuan will be responsible for providing statistical leadership and strategic regulatory input for company's projects and will report directly to Dr. Jay Mei, Chairman and CEO of Antengene. Dr. Zhinuan Yu has been working in the pharmaceutical industry for more than 20 years. Prior to joining Antengene, she was Senior Director of Biostatistics in Bristol-Myers Squibb Company. Before that, Zhinuan had served in Celgene Corporation for nearly 16 years, leading statistical support for multiple high priority programs including Thalidomide, Lenalidomide, Pomalidomide, and bb2121 (CAR-T) for multiple myeloma and other therapeutic areas, having played a key role in successful NDA/sNDA /BLA submissions with global health authorities including the US FDA, EMA, Swissmedic, Health Canada, PMDA, CFDA, and other Regulatory agencies.